Androgen Deprivation Therapy for Prostate Cancer

Androgen deprivation therapy, commonly called ADT, is the deliberate suppression of male sex hormones to slow or stop the growth of prostate cancer. Because most prostate cancers depend on testosterone to fuel their growth, cutting off that supply remains one of the most effective treatments available, used in settings ranging from localized tumors treated alongside radiation to advanced disease that has spread to bone or other organs. The approach dates back to the 1940s and has evolved considerably since then, but the basic biological logic has stayed the same. What has changed is our understanding of the ripple effects testosterone suppression sends through the rest of the body, and how to manage them.

How ADT Works

Testosterone production in men is controlled by a chain of signals that starts in the brain. The hypothalamus releases gonadotropin-releasing hormone (GnRH), which tells the pituitary gland to secrete hormones that in turn stimulate the testes to make testosterone. ADT interrupts this chain. The two main drug classes are GnRH agonists and GnRH antagonists. Both achieve the same endpoint, driving blood testosterone down to what clinicians call “castrate levels,” but they get there differently.

GnRH agonists (drugs like leuprolide and goserelin) initially overstimulate the pituitary, causing a brief spike in testosterone before the receptors become desensitized and testosterone crashes. That initial spike, sometimes called a “testosterone flare,” can temporarily worsen symptoms in men with advanced disease. GnRH antagonists like degarelix skip that flare entirely, suppressing testosterone almost immediately by blocking the GnRH receptor directly.¹ Surgical removal of the testes (orchiectomy) achieves the same hormonal result permanently and is still used in some cases, though most men opt for injectable drugs instead.

One important wrinkle: even after blood testosterone plummets to near zero, androgens do not completely vanish from prostate tumors. Research has shown that cancer tissue can retain and even generate its own low levels of testosterone through internal steroid production, which helps explain why some tumors eventually grow despite systemic hormone suppression.² This local androgen production within tumors has become a major focus of drug development.

Combining ADT With Newer Agents

For decades, ADT alone was the standard first-line treatment for advanced prostate cancer. That changed dramatically in the 2010s, when large clinical trials showed that adding a second drug to ADT significantly improved survival in men with metastatic disease that still responds to hormone therapy. The drugs tested include docetaxel (a chemotherapy), abiraterone (which blocks androgen production at multiple sites), and newer androgen-receptor inhibitors like enzalutamide and apalutamide.

A network meta-analysis comparing these combination approaches found that all four agents improved survival when added to ADT, but enzalutamide plus ADT had the lowest risk of death relative to ADT alone, with roughly a 77% probability of being the best combination for prolonging life.³ The final survival analysis of the ARCHES trial confirmed that enzalutamide plus ADT reduced the risk of death by about a third compared to ADT plus placebo, with a median follow-up of nearly four years.⁴ The upshot for patients is that ADT alone is no longer considered adequate for most men with newly diagnosed metastatic prostate cancer. Treatment intensification at the outset has become the standard.

ADT Paired With Radiation

When prostate cancer has not spread beyond the pelvis, ADT is frequently combined with radiation therapy. The hormonal treatment shrinks the tumor before and during radiation and helps mop up residual cancer cells afterward. But the question of how many months of ADT to prescribe alongside radiation has been debated for years, and the answer depends heavily on tumor risk.

A recent meta-analysis pooling data from randomized trials found that the relationship between ADT duration and benefit is not a straight line. For men with a single intermediate-risk feature, the optimal ADT duration was essentially zero, meaning radiation alone may suffice. For men with two or more intermediate-risk features, about six months of ADT appeared optimal. For high-risk disease, around twelve months yielded the best balance. Crucially, the analysis also found that extended ADT carried a near-linear increase in death from causes other than prostate cancer.⁵ That finding highlights a real tension: more ADT may control cancer better, but the metabolic and cardiovascular toll of prolonged hormone suppression can increase death from other causes.

A separate randomized trial specifically tested 36 months versus 18 months of ADT in high-risk localized disease and found no survival advantage to the longer course, supporting the idea that 18 months is a reasonable option without compromising outcomes.⁶ When brachytherapy (internal radiation) is added to external-beam radiation, the minimum ADT duration needed for optimal distant metastasis-free survival may drop to around twelve months, compared to roughly 26 months with external-beam radiation alone.⁷

Intermittent Versus Continuous Treatment

Because ADT’s side effects are significant and cumulative, researchers have long explored whether men can safely take breaks from treatment. With intermittent ADT, a man receives treatment until his PSA drops to a low level, then stops until PSA rises again, cycling on and off therapy. The appeal is obvious: during off-treatment periods, testosterone partially recovers, and many side effects improve.

A meta-analysis covering eight trials and over 5,000 patients found no meaningful difference in overall survival, cancer-specific survival, or progression-free survival between intermittent and continuous ADT.⁸ Most trials reported improved physical and sexual functioning during the off-treatment windows. A large randomized trial showed intermittent therapy was associated with better erectile function and mental health at three months, though those advantages faded over time, and the trial could not rule out a small survival disadvantage with intermittent therapy in men with metastatic disease.⁹

Intermittent ADT is now widely used for men without metastases whose PSA rises after initial treatment. In that setting, the rate of progression to castration-resistant disease appears similar whether treatment is given continuously or intermittently.¹⁰ For men with metastatic disease, most guidelines still favor continuous therapy, particularly when combined with one of the newer intensification agents.

Metabolic and Cardiovascular Side Effects

Testosterone does far more than drive prostate cancer. It influences metabolism, fat distribution, insulin sensitivity, cholesterol, red blood cell production, and vascular function. Suppressing it has consequences that ripple through nearly every organ system.

Men on long-term ADT face increased risks of insulin resistance, elevated blood sugar, unfavorable cholesterol changes, and metabolic syndrome. These metabolic shifts are a direct consequence of the severe testosterone deficiency ADT induces and may predispose patients to greater cardiovascular problems.¹¹¹²

Whether the choice of ADT drug matters for heart health has become an active research question. Multiple studies suggest that GnRH agonists cause more cardiovascular events than GnRH antagonists.¹³ A systematic review pooling data from clinical trials found that the odds of a major cardiovascular event were about 43% lower with GnRH antagonists compared to agonists.¹⁴ However, the picture is more nuanced than “antagonists are always safer.” One large study found that while the antagonist degarelix was linked to lower heart failure risk, it was associated with a higher rate of arrhythmia in men without prior heart disease.¹⁵ For men with existing cardiovascular disease, the antagonist appeared beneficial across the board, but for healthier men, the tradeoffs are less clear-cut.

Bone Loss and Fracture Risk

Testosterone plays a key role in maintaining bone density. Without it, bones thin at an accelerated rate, and men on ADT face a meaningfully elevated risk of osteoporosis and fractures. This is not a minor concern: fractures, especially vertebral and hip fractures, carry serious consequences in older men, including reduced mobility and increased mortality.

The bone-protecting drug denosumab has been specifically studied in men on ADT. In a large randomized trial, men who received denosumab every six months gained bone density at the lumbar spine, hip, and forearm, while men receiving placebo lost bone. At two years, spine density had increased by about 5.6% in the denosumab group versus a 1% loss in the placebo group. More importantly, denosumab cut the rate of new vertebral fractures from roughly 3.9% to 1.5% over three years.¹⁶ Subgroup analyses showed the benefit held even in older men, those with prior fractures, and those with the lowest baseline bone density.¹⁷ A smaller study confirmed significant spine and hip density gains with denosumab at 12 months and also found that markers of bone degradation dropped substantially.¹⁸ Bone health monitoring is now a standard part of ADT management.

Muscle Loss, Fatigue, and Body Composition

Beyond bones, testosterone suppression reshapes the body. Fat increases, particularly around the abdomen, and lean muscle mass decreases. This shift toward what researchers call sarcopenia is not just cosmetic. It affects strength, energy, balance, and long-term independence.

A prospective study following men over three years of ADT found that lean body mass dropped by about 1% at 12 months and about 2.4% by 36 months. Men aged 70 and older lost muscle roughly three times faster than younger men.¹⁹ A systematic review of body composition changes confirmed that ADT is associated with increases in fat tissue and significant declines in skeletal muscle density and mass.²⁰

Exercise is the most studied countermeasure. A systematic review of exercise interventions in men on ADT found consistent benefits in muscular strength, cardiorespiratory fitness, functional task performance, lean body mass preservation, and fatigue reduction, though effects on fat mass were inconsistent.²¹ A year-long randomized trial comparing different exercise approaches found that resistance training reduced fatigue by a clinically meaningful amount at both six and twelve months, and the men who started out the most fatigued saw the biggest gains.²² Not every trial has been equally positive. One recent randomized controlled trial found that exercise during ADT did not significantly change quality of life, fasting glucose, or body composition compared to controls, suggesting that exercise programs need to be designed carefully and that individual responses vary.²³ On balance, though, exercise remains the single most effective non-pharmacological intervention for ADT side effects, and most oncology guidelines recommend it.

Hot Flashes, Sexual Health, and Mood

Hot flashes are among the most common and most bothersome ADT side effects, affecting roughly 60 to 80% of patients. They tend to begin within a few months of starting treatment and persist long-term for most men, contrary to the common assumption that they fade with time. Up to a quarter of men describe hot flashes as the single worst quality-of-life impact of ADT.²⁴ Gabapentin has shown moderate dose-dependent effectiveness for managing hot flashes.²⁵

Loss of libido and erectile dysfunction are almost universal with continuous ADT. Erections become less frequent, less rigid, and shorter in duration. Loss of sexual desire can profoundly affect self-identity and intimate relationships, though the severity varies. Factors like age, baseline fitness, and testosterone levels before treatment influence how much sexual function deteriorates. Intermittent ADT and antiandrogen monotherapy have both been associated with somewhat better sexual outcomes than continuous combined approaches.²⁶

Mood changes are real and measurable. Men undergoing ADT report increased depression, anxiety, tension, fatigue, and irritability compared to baseline and compared to untreated controls. These changes appear within the first few months of treatment.²⁷ For many men, the emotional impact of ADT is underestimated at the outset. Clinicians sometimes focus heavily on cancer control while patients are left to discover mood and sexual side effects on their own. Open conversations before treatment begins can help set expectations and reduce distress.

Cognitive Risk and Dementia

One of the more concerning signals in ADT research is a possible link to cognitive decline and dementia. A study of over 9,000 men with prostate cancer found that those who received ADT had roughly double the risk of developing dementia compared to those who did not, with the absolute risk difference reaching about 4.4% at five years. Men on ADT for at least 12 months had the greatest risk increase.²⁸ Other observational data using GnRH agonists specifically has pointed to elevated Alzheimer’s disease risk.²⁹

A 2024 study in animal models provided a mechanistic clue: ADT appeared to disrupt the blood-brain barrier and promote immune cell infiltration into brain tissue, driving neuroinflammation and worsening cognitive deficits independently of amyloid plaque buildup. The researchers even tested whether blocking that immune cell migration with natalizumab could protect against the cognitive damage, with promising early results.³⁰ This is still preclinical work, but it suggests the cognitive effects of ADT may involve inflammatory pathways distinct from the amyloid story that dominates Alzheimer’s research. For now, the clinical takeaway is that cognitive monitoring deserves more attention in men on long-term ADT, particularly those who are older or already showing early signs of cognitive decline.

When ADT Stops Working

Nearly all advanced prostate cancers eventually develop resistance to ADT, a state called castration-resistant prostate cancer (CRPC). The cancer finds ways to reactivate androgen receptor signaling even though circulating testosterone is at rock-bottom levels. One of the best-characterized escape mechanisms involves a splice variant of the androgen receptor called AR-V7. This truncated version of the receptor is missing the portion where testosterone normally binds, which means it is always switched on, driving tumor growth without needing any hormonal fuel.³¹³²

AR-V7 has become clinically relevant as a biomarker. Detecting it in a patient’s blood, either through circulating tumor cells or exosomal RNA, appears to predict resistance to next-generation androgen-directed drugs like enzalutamide and abiraterone.³³³⁴ If AR-V7 is present, those drugs are unlikely to work, and the patient may benefit more from chemotherapy or other non-hormonal approaches. While AR-V7 testing is not yet universal in clinical practice, it represents a step toward personalizing treatment decisions rather than cycling blindly through drug classes.

GnRH Analogs Beyond Prostate Cancer

The same GnRH agonists and antagonists used in prostate cancer ADT show up in a completely different medical context: gender-affirming hormone therapy for transgender women. The pharmacology is identical. GnRH analogs like leuprolide, histrelin, and goserelin suppress testicular testosterone production by shutting down the pituitary signals that drive it. In this setting, they are typically used alongside estrogen therapy when estrogen alone does not suppress testosterone into the female range.³⁵

A systematic review of antiandrogens in transgender women found that cyproterone acetate, medroxyprogesterone acetate, and leuprolide may be more effective than spironolactone at suppressing total testosterone levels, though spironolactone’s direct blocking of the androgen receptor complicates straightforward comparisons of feminization outcomes.³⁶ Awareness of ADT’s long-term side effects in the prostate cancer population, from bone thinning and metabolic changes to cardiovascular and cognitive risks, has informed monitoring guidelines for transgender women on similar regimens, though the populations differ in important ways, including age, comorbidities, and the protective role of concurrent estrogen therapy.

The Financial Burden

Cost rarely gets discussed alongside drug mechanisms and survival curves, but for many men with prostate cancer, it is among the most pressing practical concerns. Standard injectable ADT drugs are relatively affordable and widely covered by insurance. The newer oral agents used for treatment intensification, such as enzalutamide, abiraterone, and apalutamide, are a different story. These carry substantially higher out-of-pocket costs for patients, and research has found that oral therapies for advanced prostate cancer are associated with significantly higher direct costs compared to standard ADT or chemotherapy.³⁷ This “financial toxicity” can affect treatment adherence, mental health, and daily life. Men prescribed these drugs may benefit from early conversations with social workers, financial navigators, or patient assistance programs, particularly given that treatment durations can stretch for years.